| Drug General Information |
| Drug ID |
D05PWX
|
| Former ID |
DIB005626
|
| Drug Name |
Sulfatinib
|
| Synonyms |
Anticancer agents, Hutchison; HMPL-012; Kinase inhibitors (cancer), Hutchison; VEGFR-1, 2, 3 and FGFR 1 inhibitor (oral, cancer), Hutchison
|
| Indication |
Cancer [ICD9: 140-229; ICD10:C00-C96]
|
Phase 1 |
[1]
|
|---|
| Company |
Hutchison Medipharma Enterprises Ltd
|
| Structure |
|
Download
2D MOL
3D MOL
|
| Target and Pathway |
| Target(s) |
Vascular endothelial growth factor receptor 1 |
Target Info |
Inhibitor |
[2]
|
|---|
| Basic fibroblast growth factor receptor 1 |
Target Info |
Inhibitor |
[2]
|
| Vascular endothelial growth factor receptor 2 |
Target Info |
Inhibitor |
[2]
|
| Vascular endothelial growth factor receptor 3 |
Target Info |
Inhibitor |
[2]
|
|
KEGG Pathway
|
Ras signaling pathway
|
|
Rap1 signaling pathway
|
|
Cytokine-cytokine receptor interaction
|
|
HIF-1 signaling pathway
|
|
Endocytosis
|
|
PI3K-Akt signaling pathway
|
|
Focal adhesion
|
|
Transcriptional misregulation in cancer
|
|
Rheumatoid arthritishsa04010:MAPK signaling pathway
|
|
Adherens junction
|
|
Signaling pathways regulating pluripotency of stem cells
|
|
Regulation of actin cytoskeleton
|
|
Pathways in cancer
|
|
Proteoglycans in cancer
|
|
Prostate cancer
|
|
Melanoma
|
|
Central carbon metabolism in cancerhsa04014:Ras signaling pathway
|
|
VEGF signaling pathway
|
|
Proteoglycans in cancerhsa04014:Ras signaling pathway
|
|
NetPath Pathway
|
TCR Signaling PathwayNetPath_14:IL2 Signaling PathwayNetPath_9:TNFalpha Signaling Pathway
|
|
PANTHER Pathway
|
Angiogenesis
|
|
FGF signaling pathwayP00005:Angiogenesis
|
|
VEGF signaling pathway
|
|
Pathway Interaction Database
|
Glypican 1 network
|
|
HIF-2-alpha transcription factor network
|
|
S1P3 pathway
|
|
VEGF and VEGFR signaling network
|
|
VEGFR1 specific signals
|
|
Signaling events mediated by VEGFR1 and VEGFR2glypican_1pathway:Glypican 1 network
|
|
Syndecan-4-mediated signaling events
|
|
N-cadherin signaling events
|
|
FGF signaling pathwayhif2pathway:HIF-2-alpha transcription factor network
|
|
Beta3 integrin cell surface interactions
|
|
Signaling events mediated by TCPTP
|
|
SHP2 signaling
|
|
S1P1 pathway
|
|
Integrins in angiogenesis
|
|
Signaling events mediated by VEGFR1 and VEGFR2
|
|
Notch-mediated HES/HEY networkvegf_vegfr_pathway:VEGF and VEGFR signaling network
|
|
VEGFR3 signaling in lymphatic endothelium
|
|
Reactome
|
Neurophilin interactions with VEGF and VEGFR
|
|
VEGF binds to VEGFR leading to receptor dimerizationR-HSA-194306:Neurophilin interactions with VEGF and VEGFR
|
|
VEGF binds to VEGFR leading to receptor dimerization
|
|
Integrin cell surface interactions
|
|
EPHA-mediated growth cone collapse
|
|
VEGFA-VEGFR2 Pathway
|
|
VEGFR2 mediated cell proliferationR-HSA-195399:VEGF binds to VEGFR leading to receptor dimerization
|
|
WikiPathways
|
Focal Adhesion
|
|
Signaling by VEGF
|
|
AngiogenesisWP51:Regulation of Actin Cytoskeleton
|
|
Endochondral Ossification
|
|
MAPK Signaling Pathway
|
|
Mesodermal Commitment Pathway
|
|
Hair Follicle Development: Induction (Part 1 of 3)
|
|
Integrated Pancreatic Cancer Pathway
|
|
Signaling Pathways in Glioblastoma
|
|
Neural Crest Differentiation
|
|
Signaling by FGFRWP306:Focal Adhesion
|
|
Nifedipine Activity
|
|
Cardiac Progenitor Differentiation
|
|
AngiogenesisWP1919:Signaling by VEGF
|
| References |
| REF 1 | ClinicalTrials.gov (NCT02133157) Phase I Study of Sulfatinib(HMPL-012) in Patients With Advanced Solid Tumors. U.S. National Institutes of Health. |
|---|
| REF 2 | Clinical pipeline report, company report or official report of Hutchison Medi Pharma. |
|---|
